Please login to the form below

Not currently logged in
Email:
Password:

China recalls GSK antibiotic

Chinese authorities have recalled GlaxoSmithKline's antibiotic Augmentin after traces of a compound used to make plastics more flexible were found in the treatment's syrup form

Chinese authorities have recalled GlaxoSmithKline's (GSK) antibiotic Augmentin (amoxicillin and clavulanate potassium) after traces of a compound used to make plastics more flexible were found in the treatment's syrup form.

Test results have shown the plasticiser diisodecyl phthalate (DIDP) is present in the antibiotic, according to China's State Food and Drug Administration. DIDP is banned in the production of medicines.

GSK has been ordered to immediately suspend sales of the product, which is regularly used to treat infections in children.

As reported in the UK's Daily Telegraph, a GSK spokesperson said: "GSK is currently in discussion with a number of regulatory agencies in the Asia Pacific region, some of whom have also conducted tests."

"The amount of phthalates identified as present in Augmentin syrup samples tested is very low; some tests have found none and the highest level reported by the authorities is 88 parts per million. Even this highest result is significantly lower than the levels that the US and European authorities deem as presenting no risk to humans."

Taiwan and Hong Kong had previously demanded GSK recall Augmentin after it was found to contain DIPD.

21st June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics